US FDA's GDUFA-Related FTEs Increase … Except In CBER
Executive Summary
Employees performing generic drug user fee program and related work increased nearly 68% between FY 2014 and FY 2018; Costs, as well as dependence on fees to pay for them, also increased during the period.
You may also be interested in...
US FDA Generic Approvals Break 900 Barrier In FY 2019
The record number of full ANDA approvals also exceeded submissions for the first time since GDUFA was enacted.
US FDA's Generics Program Reaches 'Steady State' Milestone
OGD Director Uhl says program is now in balance between the number of submissions and agency review actions.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.